Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib

Leukemia. 2016 Jun;30(6):1405-9. doi: 10.1038/leu.2015.303. Epub 2015 Oct 29.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Axitinib
  • Dasatinib / therapeutic use
  • Drug Screening Assays, Antitumor
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imidazoles / pharmacology*
  • Imidazoles / therapeutic use
  • In Vitro Techniques
  • Indazoles / pharmacology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / pharmacology*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyridazines / therapeutic use

Substances

  • Imidazoles
  • Indazoles
  • Protein Kinase Inhibitors
  • Pyridazines
  • ponatinib
  • Axitinib
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • Dasatinib